

Date: 30th September, 2022

BSE Limited

The Manager,
BSE Limited Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai — 400 001
BSE Scrip Code: 540359

Sub.: Outcome of 28th Annual General Meeting of the company

Dear Sirs,

Please find enclosed summary of the proceedings as required under Regulation 30, Part-A of Schedule-III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations with respect to 28th Annual General Meeting of the company held on Friday, 30th September, 2022 at 2:00 PM till 3.30 PM at the registered office of the company situated at Plot No. 20, Survey No.52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360311, Gujarat.

You are requested to take note of the same.

Thanking You.

Yours faithfully
For, **Parmax Pharma Limited**

Yash Vora
Company Secretary

Encl: As above

Summary of proceedings of 28th Annual General Meeting of the Company

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you that the following businesses were transacted at the 28th Annual General Meeting of members of Parmax Pharma Limited held on Friday, 30th September, 2022 at 2.00 pm. and concluded at 3.30 pm. at registered office of the Company, Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No.27, Hadamtala, Tal. Kotda Sangani, Rajkot. -360 311 and following businesses were transacted.

Ordinary Businesses:

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March 2022, the Audited Statement of Profit and Loss for the year ended on that date and the Reports of the Directors' and Auditors' thereon.
2. To appoint a Director in place of Dr. Umang A. Gosalia (DIN: 05153830) who retires by rotation and, being eligible, offers himself for re-appointment.

Mr. Samsad Alam Khan Practicing Company Secretary was appointed as the scrutinizer to scrutinize the remote e-voting process and e-voting process at the Annual General Meeting.

Details of voting results under Regulation 44(3) of SEBI (LODR) Regulations, 2015 will be displayed on Company's website and separately submitted with the Stock Exchanges.

This is for your information and record.

Thanking You.

Yours faithfully,

For, **Parmax Pharma Limited**

Umang Gosalia
Managing Director